Assessment of dispersion of airborne particles of oral/nasal fluid by high flow nasal cannula therapy

MC Jermy¹, CJT Spence², R Kirton², JF O'Donnell^{2.7}, N Kabaliuk¹, S Gaw⁶, Y Jiang⁴, Z Zulkhairi Abidin¹, RL Dougherty⁵, P Rowe², A Mahaliyana⁶, A Gibbs⁶, SA Roberts³

¹ Department of Mechanical Engineering, University of Canterbury, Private Bag 4800, Christchurch 8140, New Zealand

² Fisher and Paykel Healthcare, PO Box 14348, Panmure, Auckland 1741, New Zealand

³ Department of Microbiology Lab Plus, Auckland District Health Board, New Zealand

⁴ Department of Statistics, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand

⁵ Department of Mechanical Engineering, University of Kansas, Lawrence, KS66045, U.S.A.

⁶ School of Physical and Chemical Sciences, University of Canterbury, Private Bag 4800, Christchurch 8140, New Zealand

⁷ School of Nursing College of Health, Massey University, Private Bag, Auckland, New Zealand

Author contributions

MCJ, CJS, RK, SG, PR and JFO devised the measurement methods; MCJ, NK and ZZA carried out measurements and processed data; YJ carried out statistical analysis on the imaging data; SG and AM carried out the HPLC analysis; RLD advised on droplet trajectory prediction; SAR reviewed the study design and interpretation of results. MCJ, RK, PR, CJS, SAR and JFO wrote the manuscript.

Financial disclosures and conflicts of interest

CJS, JFO, RK and PR are employees of Fisher & Paykel Healthcare Ltd; YY has a consulting service agreement with Fisher & Paykel Healthcare Ltd; This study was partially funded by Fisher & Paykel Healthcare Ltd, who also provided the NHF cannulae (Optiflow) and the NHF source (Airvo/Airvo2); ZZA was supported by a scholarship from the Malaysian Ministry of Higher Education; RD was on sabbatical from the University of Kansas and was partly supported by a University of Canterbury Erskine Fellowship.

Clinical Trial Registration ACTRN12614000924651

Ethical approval

Upper South B Regional Ethics Committee, Ministry of Health, New Zealand URB/09/12/064 and the University of Canterbury Human Ethics Committee (refs. 2009/173 and HEC 2017/105).

Acknowledgements

We wish to thank Kimberly Kovacs-Wilks, Morkel Zaayman, Meike Holzenkaempfer and Amanda Inglis of the School of Physical and Chemical Sciences, University of Canterbury, for their help with the HPLC analysis.

<u>Keywords</u>

Aerosol generating procedure; nasal high flow; high flow nasal cannula; respiratory aerosol; respiratory droplets; SARS; COVID-19

Abstract

Background

Nasal High Flow (NHF) therapy delivers flows of heated humidified gases up to 60 LPM (litres per minute) via a nasal cannula. Particles of oral/nasal fluid released by patients undergoing NHF therapy may pose a cross-infection risk, which is a potential concern for treating COVID-19 patients.

<u>Methods</u>

Liquid particles within the exhaled breath of healthy participants were measured with two protocols: (1) high speed camera imaging and counting exhaled particles under high magnification (6 participants) and (2) measuring the deposition of a chemical marker (riboflavin-5-monophosphate) at a distance of 100 and 500 mm on filter papers through which air was drawn (10 participants). The filter papers were assayed with HPLC. Breathing conditions tested included quiet (resting) breathing and vigorous breathing (which here means nasal snorting, voluntary coughing and voluntary sneezing). Unsupported (natural) breathing and NHF at 30 and 60 LPM were compared.

<u>Results</u>

- (1) Imaging: During quiet breathing, no particles were recorded with unsupported breathing or 30 LPM NHF (detection limit for single particles 33 µm). Particles were detected in 2 of 6 participants at 60 LPM quiet breathing at approximately 10% of the rate caused by unsupported vigorous breathing. Unsupported vigorous breathing released the greatest numbers of particles. Vigorous breathing with NHF at 60 LPM, released half the number of particles compared to vigorous breathing without NHF.
- (2) Chemical marker tests: No oral/nasal fluid was detected in quiet breathing without NHF (detection limit 0.28 μ L/m³). In quiet breathing with NHF at 60 LPM, small quantities were detected in 4 out of 29 quiet breathing tests, not exceeding 17 μ L/m³. Vigorous breathing released 200-1000 times more fluid than the quiet breathing with NHF. The quantities detected in vigorous breathing were similar whether using NHF or not.

Conclusion

During quiet breathing, 60 LPM NHF therapy may cause oral/nasal fluid to be released as particles, at levels of tens of μ L per cubic metre of air.

Vigorous breathing (snort, cough or sneeze) releases 200 to 1000 times more oral/nasal fluid than quiet breathing. During vigorous breathing, 60 LPM NHF therapy caused no statistically significant difference in the quantity of oral/nasal fluid released compares to unsupported breathing.

NHF use does not increase the risk of dispersing infectious aerosols above the risk of unsupported vigorous breathing. Standard infection prevention and control measures should apply when dealing with a patient who has an acute respiratory infection, independent of which, if any, respiratory support is being used.

Introduction

Nasal high flow (NHF) has been increasingly used as an intervention for type 1 respiratory failure. Appropriate use of NHF has been shown to reduce intubation rates, which carries a risk of infection transmission for both patients (Frat et al. 2015, Rochwerg et al.2019), and healthcare workers (Tran et al. 2012).

Concerns have been raised about a potential risk of NHF spreading infection by generating aerosols and droplets when used to support patients with acute respiratory infections. NHF therapy is classed by some countries as an aerosol generating procedure (AGP). A systematic review of AGP and risk of transmission of acute respiratory infections (ARI) to healthcare workers (HCW) reported that more invasive respiratory procedures such as tracheal intubation, tracheotomy and manual ventilation were a significant risk factors for SARS transmission (Tran et al. 2012). This was based on a single cohort study during the SARS outbreak in Canada in 2003, which was before NHF was in clinical use (Raboud et al. 2010). In this study, lack of adherence to infection prevention and control practices was identified as a major contributor for HCW acquisition of SARS. The risk of transmission of ARI associated with AGP is very topical with the current COVID-19 pandemic. Clinicians must choose which respiratory therapies they apply, taking into consideration patient acuity, reduction of escalation, and minimizing virus transmission to healthcare workers.

Some countries or healthcare systems have guidance against using NHF for patients with COVID-19 infection, while others are using NHF as a first line therapy. Interestingly, there does not appear any substantive evidence of NHF causing large dispersions of infectious aerosols and infecting heathcare workers. In fact, the low number of relevant dispersion studies and lack of understanding of infection transmission has been highlighted in three recent publications (Bahl et al. 2020, Mittal et al. 2020, Wilson et al. 2020).

This study compares the release of particles of oral/nasal fluids during quiet resting breathing, snorting, voluntary coughing and voluntary sneezing, both in the absence of respiratory therapy and when receiving NHF at 30 and 60 LPM (litres per minute). Two techniques are used to determine volumes of oral/nasal fluid released: high speed optical video microscopy and air sampling with a chemical marker instilled into the nose and mouth. It is our hope that this data will inform evidence-based decisions about using NHF, particularly for patients with ARI.

Methods

Definitions

In the terminology commonly accepted in healthcare, aerosols are suspensions of small particles, including droplet nuclei, with an aerodynamic diameter of 10 μ m or less. Droplets are particles with an aerodynamic diameter of > 10 μ m. Airborne transmission in a healthcare setting refers to transmission by aerosols of < 10 μ m (Tellier et al. 2019). Particles in either size class can be inhaled, causing virus transfer, depending on proximity and air currents.

(1) Imaging method

Six healthy volunteers participated: three females aged 20 to 27 years, and three males aged 26 to 59 years. Participants wore a medium size Optiflow[™] (OPT544, Fisher & Paykel Healthcare, Auckland, New Zealand) NHF cannula. Air flows conditioned to 37°C and 100% relative humidity (44mg/L) were generated with an AIRVO[™] 2 humidifier-flow generator (Fisher & Paykel Healthcare). Participants were instructed to breathe with their mouth closed to create higher nasal velocities more likely to release particles. All participants spent at least five minutes acclimatizing to NHF at 30 LPM. Prior to each measurement, 1 mL of 0.9% NaCl solution was instilled into each nostril to artificially moisten the nasal mucosa. Saline has a lower viscosity than nasal mucous and is more easily atomized. 1 ml was assumed sufficient as excess ran out of the nose.

Participants sat with their chin and forehead on a rest. A region of approximately 40×30 mm directly below the participants' nostrils was imaged with a high-speed camera (Motion Pro X3TM, 1040 frames per second, shutter speed of 40 µs and resolution 1280×1024 pixels, Redlake Imaging Corp.). The region was backlit such that particles and the outline of the nose cast a shadow onto the camera (Figure 1). The left and right nostrils were imaged separately because the camera's depth of field (20mm) could encompass only one nostril entirely.

Videos were analyzed using a Java-based image processing program (Image J, National Institutes of Health, Bethesda, MD, USA) for particle frequency, diameter and velocity. The number of particles were recorded in bins with diameter of 0-50, 50-100, 100-150, 200-500, 500-1000, 1000-2000 and 2000-5000 μ m. The smallest detectable particle occupies one pixel i.e. has a diameter of 33.0 μ m.



Figure 1: Imaging Layout

The experimental conditions were:

- Quiet breathing (at rest) with no therapy, with 30LPM NHF, and with 60LPM NHF.
- Voluntary snort (mouth-closed maximum effort nasal exhale) with no therapy, with 30LPM NHF, and with 60LPM NHF.

There were three repeats at each experimental condition.

Chemical marker method

Ten healthy volunteers (aged 23-48, 1 female and 9 male) participated. Participants sat in a chair with a headrest. Each participant carried out the sequence of actions described in Table 1. The order of the notherapy and 60 LPM therapy actions was randomized. Participants acclimatized to the 60 LPM therapy for a few minutes before beginning the NHF tests. Where NHF was used, an Optiflow[™]+ cannula (OPT946, OPT944, OPT942) was selected, and was used with an Airvo[™]2 humidifier set to 37°C and 100% relative humidity (44 mg/L). Immediately before each measurement, the participant instilled 0.5 mL of marker solution into each nostril, and for coughing and sneezing, an additional 1 mL onto their tongue, via pipette. The marker solution was 2.8 grams of riboflavin 5' monophosphate sodium salt hydrate (Sigma-Aldrich, St Louis, MO, USA, F6750-25G, fluorimetric grade, 73-76% purity) per litre of deionized water.

Action	Therapy	repeats	Sampling distance	Duration
Quiet breathing	No therapy	2-3	1-2 at 100 mm;	7 mins
			1 at 500 mm	
Voluntary snort (mouth closed, expel air	No therapy	1	500 mm	30 sec
through nose with maximum effort)				
Voluntary cough (mouth open)	No therapy	1	500 mm	30 sec
Voluntary sneeze (allow mouth to open)	No therapy	1	500 mm	30 sec
Quiet resting breathing	60 LPM	2-3	1-2 at 100 mm;	7 mins
			1 at 500 mm	
Voluntary snort (mouth closed, expel air	60 LPM	1	500 mm	30 sec
through nose with maximum effort)				
Voluntary cough (mouth open)	60 LPM	1	500 mm	30 sec
Voluntary sneeze (allow mouth to open)	60 LPM	1	500 mm	30 sec

Table 1: Actions for chemical marker test.

Air was sampled at a distance of either 100 mm or 500 mm from the participant's nose, using 125 mm diameter qualitative filter paper (Whatman plc, Little Chalfont, Bucks, UK, product number 1005-125) supported on an acrylic grille through which air was drawn at 2.2-18.1 LPM with a vacuum pump. The air flow rate was measured with a TSI 4040 meter (TSI Inc. Shoreview, MN, USA). This sampling system was placed to intercept the maximum exhaled nasal velocity, determined for each test after the participant found a position they could maintain comfortably for the duration. The filter papers were stored in Petri dishes (used as delivered in clean sterile packaging) and frozen for later analysis. A clean grille was used after each block of quiet breathing tests, and after each snort, cough or sneeze.

Background measurements (7 min duration) were run before and after each participant. No riboflavin was detected in any of these, indicating the room ventilation was adequate to prevent contamination between tests.

For quantitative analysis, the samples were brought to room temperature and riboflavin was extracted from the filter paper using 3.5 ml of Milli-Q water (Merck Millipore, Burlington, MA, USA) with 5 minutes of gentle agitation. 1.5 mL of the supernatant was drawn off and expelled through a 0.45 μ m filter into HPLC vials. These were analyzed with a Dionex UHPLC Focused (Thermo Fisher Scientific, Waltham, MA, USA) fitted with an autosampler, Ultimate® 3000 pump, and Ultimate® 3000 fluorescence detector. 20 μ L samples were injected into a Kinetex 5 μ m C18 100 Å, 100 x 2.1 mm LC Column (Phenomenex, Torrance, CA, USA). The mobile phase was 95% NH₄HCO₃ and 5% methanol. Samples were run at a column temperature of 35°C, pressure of 62 bar and an isocratic flow rate of 0.2 mLPM for a total run time of 36 minutes.

A six-point external standard calibration curve (0, 50, 100, 200, 400, 800 and 1000 ng/mL) of 95% purity riboflavin 5' monophosphate (Sigma Aldrich, F8399) was used for the quantification of samples and the calibration standards were analyzed prior to starting the sample sequence. Milli-Q blanks were analyzed after the calibration standards and after every 14 samples to ensure there was no carry-over from the

previous runs. A 100 ng/mL check standard was run after every sample sequence to confirm the validity of the calibration curve. Calibration standards and samples were analyzed in duplicate aliquots. Chromeleon (c) Dionex (Version 7.2.7.10369) software was used for peak fitting and calibration.

The concentration of oral/nasal fluid emitted by the participant and collected by the sampling system was calculated using the concentration of the riboflavin, the air flow rate through the filter paper, the duration of the test, and the volume of Milli-Q water used to extract the riboflavin.

The duplicate aliquots agreed within 4% except for two instances in which four overlapping peaks were fitted at the riboflavin retention time.

The detection limit was determined by visual assessment of the signal-to-noise ratio to be 2.75 ng/ml riboflavin per unit volume of supernatant, which was equivalent to the concentrations of oral/nasal fluid given in Table 2.

Air flow rate (LPM)	Test duration (min)	Detection limit (µL oral/nasal
		fluid per m³ air)
2.5	0.5	3.6
18.1	0.5	0.5
2.3	7	0.28
12.7	7	0.05

Table 2: Detection limits of oral/nasal fluid

Results

(1) Imaging

During quiet breathing with no therapy and with 30 LPM NHF, no particles were detected for any of the participants tested. Particles were detected during quiet breathing with 60 LPM NHF, for two of the six participants.

When snorting, five out of six participants produced visible particles in all conditions. An example image is shown in Figure 2. The particles ranged in diameter from the smallest detectable size of 33 μ m to 5000 μ m (5mm) in diameter. Interpersonal variation was large. One (female) participant produced no detectable particles with NHF at 60LPM.



Figure 2 Particles during snort, no therapy (left) and snort, 60 LPM NHF (right). From top to bottom on the right of each image is a silhouette of a participant's nose, lips (left image) or nasal cannula (right image) and chin.

The number of particles detected (mean, minimum and maximum), are given in Table 3 and Figure 3 as a function of size. The depth of focus limits the accuracy of the size measurement. Data are shown only for the four experimental conditions in which particles were present. The values are averaged over three repeats on each the left and right nostril. There were no observed differences between left and right nostrils so the data were combined for analysis.

Particle Quiet breathing, 60 LPM				Snort, no therapy			Snort, 30 LPM			Snort, 60 LPM				
(μm)	Mean	Min	Max		Mean	Min	Max	Mean	Min	Max	Mean	Min	Max	
50	0.8	0.0	2.5		5.0	0.0	18.3	3.0	0.0	10.5	3.4	0.0	9.9	
100	2.5	0.0	10.0		14.7	0.0	46.7	9.7	0.0	38.3	11.9	0.0	34.1	
150	2.5	0.0	10.2		28.9	0.5	121.0	14.7	0.0	59.2	18.4	1.2	62.9	
200	2.6	0.0	10.3		26.4	1.7	101.0	11.6	0.0	39.3	16.0	1.4	50.7	
500	5.9	0.0	21.0		72.9	2.7	276.8	30.4	0.0	119.3	45.9	6.3	136.3	
1000	0.6	0.0	2.7		24.0	1.0	78.8	9.6	0.0	28.5	10.2	1.7	24.6	
2000	0.1	0.0	0.3		6.1	0.3	19.7	1.3	0.0	3.5	0.8	0.0	3.2	
5000	0.1	0.0	0.5		0.6	0.0	2.5	0.0	0.0	0.0	0.0	0.0	0.1	

 Table 3: Summary of average particle numbers across six participants and for the four conditions for which particles were detected.



Figure 3: Number of particles (averaged over both nostrils and all participants)

(2) Chemical marker

The calculated quantities of oral/nasal fluid in the air captured by the sampler are given in **Table 4**, together with the mean and standard deviations calculated over all participants. The data is summarized in Figure 4. The second quiet breathing, 100 mm distance test was omitted for Participant Four due to time limitations.

			μL oral/nasal fluid per cubic metre of air											
			Participant											
		Dist												
	Therapy	(mm)	1	2	3	4	5	6	7	8	9	10	Mean	s.d.
Quiet	No	100	0	0	0	0	0	0	0	0	0	0	-	-
Quiet	No	100	0	0	0	Omitted	0	0	0	0	0	0	-	-
Quiet	No	500	0	0	0	0	0	0	0	0	0	0	-	-
Snort	No	500	260	2,843	27.6	11.9	145	30.5	13,786	678	2,419	259	2,046	4,252
Cough	No	500	5.13	19.4	38.7	117	24.9	0.00	4,233	1,080	10.1	804	633	1,323
Sneeze	No	500	2,507	48.3	0.00	66.2	110	132	3,445	2,379	193	10,219	1,910	3,194
Quiet	60 LPM	100	0.00	0.00	0.00	1.68	6.12	0.00	0.00	0.00	0.00	0.00	0.78	1.95
Quiet	60 LPM	100	0.00	0.00	17.0	Omitted	0.00	0.00	0.00	0.00	0.26	0.00	1.72	5.64
Quiet	60 LPM	500	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-
Snort	60 LPM	500	13.2	1,424	21.0	21.1	43.2	980	489	86.2	1,541	211	483	608
Cough	60 LPM	500	157	606	37.8	17.5	0.00	106	15,274	3,484	335	382	2,040	4,766
Sneeze 60 LPM 500		1,327	9.71	31.2	26.4	12.8	60.3	2,133	8,739	249	923	1,351	2,695	

Table 4: Results of the chemical marker tests. Values for each subject are the mean of the duplicate aliquots.



Figure 4: Summary of data from chemical marker test. Black circles are the means, error bars are +/- one standard deviation (due to the logarithmic scale, the negative error bar is obscured by the datapoint marker), and bars show the range from minimum to maximum. White bars are no therapy, grey bars are 60 LPM NHF. The solid line is the maximum detectability limit and the dashed line is the minimum (as detectability depends on air flow rate).

Oral/nasal fluid was not detected in quiet resting breathing without NHF therapy. Oral/nasal fluid was detected 4 times in 29 tests in quiet breathing with NHF therapy. It never exceeded 17 μ L per cubic metre of sampled air, and counting only those instances where it was detected, it was at a mean level of 6.3 μ L per cubic metre of sampled air. This was 1/200 th of the average level detected in snort, cough or sneeze. It was detected in two cases during quiet breathing where this was the first action the participant did, and in two cases where they completed no-therapy actions first.

With no therapy, oral/nasal fluid was detected in quantities exceeding 633 μ L per cubic metre in all snorts, nine out of ten coughs, and nine out of ten sneezes.

With NHF (60 LPM), oral/nasal fluid was detected in quantities exceeding 483 μ L per cubic metre in all snorts, 9 out of 10 coughs, and all sneezes.

Snort, cough and sneeze all release the same order of magnitude of oral/nasal fluid. The quantities detected in with-therapy and no-therapy cases are of similar order of magnitude.

Discussion

To our knowledge this is the first study to compare the optical video-microscopy and chemical marker methods for oral/nasal fluid dispersion in the presence and absence of NHF. It was evident from both measurement modalities that high energy respiratory maneuvers like coughing, sneezing and snorting generated high volumes of particles, either with or without NHF, compared to quiet breathing. Higher expired flow velocities are expected to generate stronger shear forces over the mucosa, generating more airborne particles (Mittal et al. 2020). Interestingly, the higher therapy flow rate (60 LPM) released more particles than 30 LPM, but not twice as many.

During vigorous breathing there were fewer particles produced with NHF than without NHF. This was true at both flow rates in the imaging tests, and true when averaged over snort, cough and sneeze in the marker tests. NHF's apparent mitigation of particle generation during vigorous breathing may be explained by particles impacting on the cannula interface. Another possible explanation is that NHF imposes an expiratory flow resistance that increases expiratory time (Mundel et al. 2013) and reduces the peak expiratory flow (Spence et al. 2010). Although NHF contributes to higher nasal velocities (Spence et al. 2012), patient peak expiratory velocities are lower and particle generation reduced. There is high interpersonal variation in both datasets, with standard deviations typically twice the mean. Besides interpersonal differences in mucosa and air velocity, the air sampling does not capture the entire particle plume.

For the oral/nasal fluid collection, it should be noted that with quiet breathing alone there were no detectable levels in the twenty nine measurements, while the addition of 60 LPM NHF increased this to four out of twenty nine tests with detectable volumes. However, these quiet breathing measurements were taken over a seven-minute period, and produced 200 to 1000 times lower volumes of oral/nasal fluid than the higher energy respiratory maneuvers of coughing, sneezing and snorting achieved in a 30 second period. Looking at this another way, coughing with no therapy produced 633 μ L/m3 in half a minute i.e. (1,266 μ L/m3/min). Quiet breathing with NHF at 60 LPM produced on average 1.72 μ L/m3 in 7 minutes (0.246 μ L/m3/min). It would take 86 hours of quiet breathing with NHF at 60 LPM times as long to release the same quantity of oral/nasal fluid as a minute of coughing with no therapy (1,266/1.72=5,146 mins or 86 hours). Cough is a common symptom for coronavirus, with a recent study reporting an average cough frequency of 17 events in a 30 min test (Leung et al. 2020).

It has been postulated that a higher clinical acuity Acute Respiratory Distress Syndrome (ARDS) patient will generate more particles due to a higher work of breathing, increased closing capacity and altered respiratory tract fluid (Wilson et al. 2020). In a recent study using a green laser and an iPhone camera, it was demonstrated that a healthy participant generates droplets/particles when speaking, with the number of detectable particles increasing with speech volume. The number of particles was markedly reduced when talking through a slightly damped washcloth (Anfinrud et al. 2020). In an ICU based study by Leung et al. (2019), Petri dishes were positioned at 0.4 and 1.5 m around critically ill patients with Gram-negative bacterial pneumonia. The results suggested that there was no increase of surface or air contamination using NHF compared to conventional oxygen masks (Leung et al. 2019). A simulation breathing manikin and smoke generation system, in conjunction with laser sheet light and high resolution imaging system was used to quantify air dispersion in some elegant research by Hui et al. (2014, 2019).

The simulation work demonstrated that NHF was no worse, and was arguably better, than the CPAP systems used as a comparison. A study using a manikin assessed the potential for pathogen dispersal during NHF and found detection of water and yeast only in the proximal locations, < 60 cm from the face (Kotoda et al. 2020).

One study had five healthy participants sit in a chair, gargle 10 ml of food coloring then cough, and measure how far the visible droplets went on paper on the floor. They reported that the discernable particles traveled on average 2.48 m with no therapy and 2.91 m with NHF at 60 LPM (Loh et al. 2020). While this rudimentary methodology implies NHF may have increase the dispersion distance slightly, both are further than the 2 m frequently stated as a safe distance in guidelines (Bahl et al., 2020). These findings were reinforced by a study from two hospitals in Wuhan, China that measured the dispersion distance of Coronavirus 2 in the ICU and ward environments, and found virus nucleic acid up to 4 m from the patient beds (Gou et al. 2020).

The study's findings are in general concordance with these other published studies of particle dispersion with NHF. However there is still a dearth of high quality data regarding aerosol and droplet generation, and this should be resolved to improve the understanding of the possible mechanism of transmission, and to inform evidence based guidelines for health care workers treating patients infected with Covid-19 and related diseases (Bahl et al. 2020).

Many clinical interventions and therapies are considered to have the potential to generate aerosols, including standard oxygen therapy, non-invasive ventilation, intubation, nebulisation and NHF therapy. It is important to gain a full understanding of the potential benefits of using any of these therapies in the context of any associated risks. The mechanism of droplet and aerosol virus transmission is also not fully understood. The emerging evidence suggests the generation of numbers of particles increases with the vigor of the respiratory activity.

The potential benefits of using NHF therapy should be weighed against the risks. One of the primary indications for use of NHF is treating type 1 respiratory failure. In a large RCT conducted in 23 ICU's in France and Belgium involving 310 participants, NHF was reported to reduce intubation rates compared to non-rebreather face mask or NIV for a subgroup of those with Acute Hypoxic Respiratory Failure (AHRF) and a PaO2:FIO2 of 200 mm Hg or less, of whom the majority had community acquired pneumonia (Frat et al. 2015). This study by Frat et al. (2015) was one of nine RCTs synthesized in a meta-analysis comparing standard oxygen to NHF in AHRF (Rochwerg et al. 2019). The results of this meta-analysis suggested a reduced intubation rate and escalation of oxygen therapy (Rochwerg et al. 2019). It could be argued that if using NHF reduces the need for intubation, employing a pragmatic approach could improve the outcome for the patient, by reducing the use of more invasive therapies, and reduce the exposure risk to the HCW.

A systematic review of SARS-related literature conducted to understand the risk of transmission to healthcare workers from aerosol-generating procedures (Tran et al. 2012), reported that intubation was a high-risk procedure. The same review reported oxygen, high flow oxygen or BiPap mask were low risk. There is also some evidence that humidity may play a role in preserving the ability of the mucous membrane to resist the infection (Lauc et al. 2020), modelling work that suggests increased humidity may

inhibit the displacement of expelled particles (Xie et al. 2007), and that coronaviruses are humidity and temperature sensitive (Lauc et al. 2020), so there is speculation the higher temperatures and humidity levels of NHF might reduce the viable virus dispersion compared to dry gas therapy. In one recent study on COVID-19 patients, NHF was reported to be the most common ventilation support, although it was used to greater success in the patients with PaO2/FiO2 ratios above 200. (Wang et al. 2020)

There is speculation that NHF may increase the chances of aerosol generation and COVID-19 transmission. However, there is a lack of evidence to support that NHF is any worse than other low risk respiratory therapy such as oxygen therapy or NIV, and its use may avoid the need for high risk procedures such as intubation.

This study had numerous limitations: all participants were healthy; there was a narrow age distribution (although previous research indicates no reason to expect different results from other participants. Tobin et al. (1983), for example, measured the breathing patterns of 65 healthy participants from 20 to 81 years of age and found no effect of age on the mean values of various breathing pattern components); all participants were in a sitting position and a supine position may give different results; the imaging could not detect particles of less than 33 microns in diameter; the chemical marker could not discriminate on particle size, and due to the limited physical size of the filter paper, might not collect all of the discharge plume. In both methods, some of the sample fluid used to moisten the mucosa was swallowed. In both methods the instilled fluid was either saline or water and as such, be more easily atomized and/or produce smaller diameter particles. There was considerable variability in the results. It is speculated that this large variability is due to a range of factors including: some of the 1 ml sample going down the throat premeasurement, and the variability of simulated snorting, coughing and sneezing.

Conclusions

60 LPM NHF therapy may cause some small quantity of oral/nasal fluid to be released during quiet breathing, at levels of less than 17 μ L per cubic metre of air. The addition of a filter barrier may be indicated.

Vigorous breathing (snort, cough or sneeze) releases 200 to 1000 times more oral/nasal fluid than quiet breathing.

60 LPM NHF does not make the levels of oral/nasal fluid emitted during cough, snort or sneeze greater compared to unsupported breathing.

We do not find evidence for large numbers of particles being dispersed by NHF, compared to cough or sneeze. NHF is a useful therapy for Type 1 Respiratory failure and reducing escalation to high infection risk procedures like intubation.

Vigorous breathing without NHF is the worst-case scenario that should drive infection prevention and control measures. The use of NHF, per se, does not increase the risk of generation of infectious airborne aerosols above the risk of patient-generated aerosols. Adherence to standard infection prevention and control measures such as 'Contact and Droplet Precautions' (Tran et al. 2013) is sufficient when NHF is applied.

References

Anfinrud P, Stadnytskyi V, Bax CE, Bax A. Visualizing Speech-Generated Oral Fluid Droplets with Laser Light Scattering [published online ahead of print, 2020 Apr 15]. N Engl J Med. 2020;NEJMc2007800. doi:10.1056/NEJMc2007800

Bahl P, Doolan C, de Silva C, Chughtai AA, Bourouiba L, MacIntyre CR. Airborne or droplet precautions for health workers treating COVID-19? [published online ahead of print, 2020 Apr 16]. J Infect Dis. 2020;jiaa189. doi:10.1093/infdis/jiaa189

Frat JP, Thille AW, Mercat A, et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med. 2015;372(23):2185-2196. doi:10.1056/NEJMoa1503326

Guo ZD, Wang ZY, Zhang SF, et al. Aerosol and Surface Distribution of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospital Wards, Wuhan, China, 2020 [published online ahead of print, 2020 Apr 10]. Emerg Infect Dis. 2020;26(7):10.3201/eid2607.200885. doi:10.3201/eid2607.200885

Hui DS, Chan MT, Chow B. Aerosol dispersion during various respiratory therapies: a risk assessment model of nosocomial infection to health care workers. Hong Kong Med J. 2014;20 Suppl 4:9-13.

Hui DS, Chow BK, Lo T, et al. Exhaled air dispersion during high-flow nasal cannula therapy versus CPAP via different masks. Eur Respir J. 2019;53(4):1802339. Published 2019 Apr 11. doi:10.1183/13993003.02339-2018

Kotoda M, Hishiyama S, Mitsui K, et al. Assessment of the potential for pathogen dispersal during high-flow nasal therapy. J Hosp Infect. 2020;104(4):534-537. doi:10.1016/j.jhin.2019.11.010

Lauc G, Markotić A, Gornik I, Primorac D. Fighting COVID-19 with water. J Glob Health. 2020;10(1):010344. doi:10.7189/jogh.10.010344

Leung CCH, Joynt GM, Gomersall CD, et al. Comparison of high-flow nasal cannula versus oxygen face mask for environmental bacterial contamination in critically ill pneumonia patients: a randomized controlled crossover trial. J Hosp Infect. 2019;101(1):84-87. doi:10.1016/j.jhin.2018.10.007

Leung, N.H.L., Chu, D.K.W., Shiu, E.Y.C. et al. Respiratory virus shedding in exhaled breath and efficacy of face masks. Nat Med 26, 676–680 (2020). https://doi.org/10.1038/s41591-020-0843-2

Loh NW, Tan Y, Taculod J, et al. The impact of high-flow nasal cannula (HFNC) on coughing distance: implications on its use during the novel coronavirus disease outbreak [published online ahead of print, 2020 Mar 18]. Can J Anaesth. 2020;1-2. doi:10.1007/s12630-020-01634-3

Mittal, R., Ni, R., & Seo, J. (2020). The flow physics of COVID-19. Journal of Fluid Mechanics, 894, F2. doi:10.1017/jfm.2020.330

Mundel T, Feng S, Tatkov S, et al. Mechanisms of nasal high flow on ventilation during wakefulness and sleep. J Appl Physiol 2013

Raboud J, Shigayeva A, McGeer A, Bontovics E, Chapman M, et al. (2010) Risk Factors for SARS Transmission from Patients Requiring Intubation: A Multicentre Investigation in Toronto, Canada. PLoS ONE 5(5): e10717. doi:10.1371/journal.pone.0010717

Rochwerg B, Granton D, Wang DX, et al. High flow nasal cannula compared with conventional oxygen therapy for acute hypoxemic respiratory failure: a systematic review and meta-analysis. Intensive Care Med. 2019;45(5):563-572. doi:10.1007/s00134-019-05590-5

Spence CJT, Buchmann NA, Jermy MC, et al. Stereoscopic PIV measurements of flow in the nasal cavity with high flow therapy. Experiments in Fluids 2010; 50:1005-1017

Spence CJT, Buchmann NA, Jermy MC. Unsteady flow in the nasal cavity with high flow therapy measured by stereoscopic PIV. Experiments in Fluids 2012; 52:569-579

Tellier R, Li Y, Cowling BJ, Tang JW. Recognition of aerosol transmission of infectious agents: a commentary. BMC Infect Dis. 2019;19(1):101. Published 2019 Jan 31. doi:10.1186/s12879-019-3707-y

Tobin MJ, Chadha TS, Jenouri, Birch, Gazeroglu, Sackner, "Breathing patterns 1. Normal Subjects" Chest 1983;84(2):202-205.

Tran K, Cimon K, Severn M, Pessoa-Silva C, Conly J. Aerosol-generating procedures and risk of transmission of acute respiratory infections: a systematic review. CADTH Technol Overv. 2013;3(1):e3201.

Wang K, Zhao W, Li J, Shu W, Duan J. The experience of high-flow nasal cannula in hospitalized patients with 2019 novel coronavirus-infected pneumonia in two hospitals of Chongqing, China. Ann Intensive Care. 2020;10(1):37. Published 2020 Mar 30. doi:10.1186/s13613-020-00653-z

Wilson NM, Norton A, Young FP, Collins DW. Airborne transmission of severe acute respiratory syndrome coronavirus-2 to healthcare workers: a narrative review [published online ahead of print, 2020 Apr 20]. Anaesthesia. 2020;10.1111/anae.15093. doi:10.1111/anae.15093

Xie X, Li Y, Chwang AT, Ho PL, Seto WH. How far droplets can move in indoor environments--revisiting the Wells evaporation-falling curve. Indoor Air. 2007;17(3):211-225. doi:10.1111/j.1600-0668.2007.00469.x